Post hoc analysis of ONWARDS 1–5 trials suggests no additional increase in #PhysicalActivity-attributed #hypoglycaemia risk with once-weekly #insulin icodec vs once-daily basal insulins in #T2D. link.springer.com/article/10.1... 🔓
April 22, 2025 at 8:40 AM
Post hoc analysis of ONWARDS 1–5 trials suggests no additional increase in #PhysicalActivity-attributed #hypoglycaemia risk with once-weekly #insulin icodec vs once-daily basal insulins in #T2D. link.springer.com/article/10.1... 🔓
Post hoc analysis of ONWARDS 1–5 trial data indicating no additional increase in #hypoglycaemia risk attributed to #PhysicalActivity with once-weekly #insulin icodec vs once-daily basal insulins in #T2D #DiabetesResearch #Endocrinology #MedSky
Post hoc analysis of ONWARDS 1–5 trials suggests no additional increase in #PhysicalActivity-attributed #hypoglycaemia risk with once-weekly #insulin icodec vs once-daily basal insulins in #T2D. link.springer.com/article/10.1... 🔓
April 23, 2025 at 8:39 AM
Post hoc analysis of ONWARDS 1–5 trial data indicating no additional increase in #hypoglycaemia risk attributed to #PhysicalActivity with once-weekly #insulin icodec vs once-daily basal insulins in #T2D #DiabetesResearch #Endocrinology #MedSky